Osivax Receives Over USD 1.5M Grant from NIAID to Advance Development of Broad-Spectrum Influenza Vaccine Candidate, OVX836

11 December 2023

Lyon, France – December 5, 2023 – Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses, today announced that it has received a grant of over USD 1.5M from the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health (NIH). The grant (project number 1R01AI177376) will support preclinical studies evaluating the breadth of protection and immune response induced by the company’s lead, broad-spectrum influenza vaccine candidate, OVX836 against pandemic influenza strains.

The preclinical studies are planned to be conducted at the Infectious Diseases Models for Innovative Therapies (IDMIT) department at the French Alternative Energies and Atomic Energy Commission (CEA) site in Fontenay-aux-Roses, France. The IDMIT is highly specialized in human infectious diseases and has the facilities needed for testing the immunogenicity and efficacy of OVX836 as a vaccine against pandemic influenza strains in preclinical models. To know more